FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1899351010> ?p ?o ?g. }

• W1899351010 endingPage "170" @default.
• W1899351010 startingPage "163" @default.
• W1899351010 abstract "Vitiligo is a systemic dermatological disorder characterized by the loss of skin pigmentation due to melanocyte injury or aberrant functioning. Recent data underline its multifactorial etiology with significant involvement of autoimmune and redox alterations. The major role in vitiligo cellular immunity is displayed by augmented Th1 and Th17 and suppressed TREGs and Th2 lymphocyte populations. Our previous studies indicate a marked redox imbalance in perilesional (PL, i.e. obtained from visibly unaffected skin surrounding the depigmented area in vitiligo patients) keratinocytes where the massive infiltration of inflammatory cells takes place. No defined therapy exists for vitiligo. Although a number of approaches have been used for the induction of TREGs and Th2 cells, they may be associated with significant off-target effects.In order to identify a targeted approach for vitiligo treatment we, first, aimed to investigate the possible source of ROS overproduction in PL keratinocytes. Second, we tested the effect of low-dose selected cytokines, on intra- and extracellular ROS production, cell viability and cell cycle of PL keratinocytes.The in vitro study was conducted on primary PL keratinocytes obtained from the skin of vitiligo patients in our previous studies. The activity of NADPH oxidase was measured on intact PL and control keratinocytes, treated or not with cytokines, by luminometric assay. The following cytokines were selected for PL keratinocytes treatment: IL-10 and IL-4 (produced by TREGs and Th2, respectively), basic fibroblasts growth factor (bFGF) and neuropeptide β-endorphin (modulating the cellular resistance to oxidative stress and the immune response, respectively). All cytokines were used at concentration of 10fg/ml and were prepared by sequential-kinetic-activation (SKA). Intracellular ROS production and cell cycle were analyzed by flow cytometry using H2DCFDA and propidium iodide dyes, respectively. Cell viability was measured by fluorometric resazurin reduction method.Our results suggest that NADPH oxidase represents one of the main sources of ROS overproduction by PL keratinocytes. Further, SKA low-dose IL-10, β-endorphin and, particularly, IL-4 and bFGF display a positive effect on redox dyshomeostasis and viability and, in our experimental conditions, don't affect the cell cycle of PL keratinocytes.Our preliminary data suggest that low-dose IL-10, IL-4, β-endorphin and bFGF can be proposed as a new therapeutic tool for vitiligo treatment." @default.
• W1899351010 created "2016-06-24" @default.
• W1899351010 creator A5009727581 @default.
• W1899351010 creator A5026898710 @default.
• W1899351010 creator A5032609098 @default.
• W1899351010 creator A5037326193 @default.
• W1899351010 creator A5047331345 @default.
• W1899351010 creator A5050873341 @default.
• W1899351010 date "2015-08-01" @default.
• W1899351010 modified "2023-10-17" @default.
• W1899351010 title "Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin" @default.
• W1899351010 cites W1602488051 @default.
• W1899351010 cites W1909526655 @default.
• W1899351010 cites W1967187858 @default.
• W1899351010 cites W1973087517 @default.
• W1899351010 cites W1976734129 @default.
• W1899351010 cites W1980608786 @default.
• W1899351010 cites W1983805005 @default.
• W1899351010 cites W1992145267 @default.
• W1899351010 cites W2004401720 @default.
• W1899351010 cites W2012231950 @default.
• W1899351010 cites W2016795513 @default.
• W1899351010 cites W2020303539 @default.
• W1899351010 cites W2024047046 @default.
• W1899351010 cites W2026194063 @default.
• W1899351010 cites W2030531265 @default.
• W1899351010 cites W2038082197 @default.
• W1899351010 cites W2055539585 @default.
• W1899351010 cites W2056881681 @default.
• W1899351010 cites W2061427976 @default.
• W1899351010 cites W2076152557 @default.
• W1899351010 cites W2081658396 @default.
• W1899351010 cites W2092329780 @default.
• W1899351010 cites W2093563591 @default.
• W1899351010 cites W2100509244 @default.
• W1899351010 cites W2117147802 @default.
• W1899351010 cites W2131678280 @default.
• W1899351010 cites W2143819913 @default.
• W1899351010 cites W2144494828 @default.
• W1899351010 cites W2151088826 @default.
• W1899351010 cites W2163736174 @default.
• W1899351010 cites W1993072988 @default.
• W1899351010 doi "https://doi.org/10.1016/j.jdermsci.2015.05.003" @default.
• W1899351010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26051876" @default.
• W1899351010 hasPublicationYear "2015" @default.
• W1899351010 type Work @default.
• W1899351010 sameAs 1899351010 @default.
• W1899351010 citedByCount "50" @default.
• W1899351010 countsByYear W18993510102015 @default.
• W1899351010 countsByYear W18993510102016 @default.
• W1899351010 countsByYear W18993510102017 @default.
• W1899351010 countsByYear W18993510102018 @default.
• W1899351010 countsByYear W18993510102019 @default.
• W1899351010 countsByYear W18993510102020 @default.
• W1899351010 countsByYear W18993510102021 @default.
• W1899351010 countsByYear W18993510102022 @default.
• W1899351010 countsByYear W18993510102023 @default.
• W1899351010 crossrefType "journal-article" @default.
• W1899351010 hasAuthorship W1899351010A5009727581 @default.
• W1899351010 hasAuthorship W1899351010A5026898710 @default.
• W1899351010 hasAuthorship W1899351010A5032609098 @default.
• W1899351010 hasAuthorship W1899351010A5037326193 @default.
• W1899351010 hasAuthorship W1899351010A5047331345 @default.
• W1899351010 hasAuthorship W1899351010A5050873341 @default.
• W1899351010 hasBestOaLocation W18993510102 @default.
• W1899351010 hasConcept C134018914 @default.
• W1899351010 hasConcept C164027704 @default.
• W1899351010 hasConcept C203014093 @default.
• W1899351010 hasConcept C2776151105 @default.
• W1899351010 hasConcept C2776914184 @default.
• W1899351010 hasConcept C2777074287 @default.
• W1899351010 hasConcept C2777658100 @default.
• W1899351010 hasConcept C2778690821 @default.
• W1899351010 hasConcept C2779769559 @default.
• W1899351010 hasConcept C2779980618 @default.
• W1899351010 hasConcept C502942594 @default.
• W1899351010 hasConcept C54355233 @default.
• W1899351010 hasConcept C71924100 @default.
• W1899351010 hasConcept C81885089 @default.
• W1899351010 hasConcept C86803240 @default.
• W1899351010 hasConcept C8891405 @default.
• W1899351010 hasConceptScore W1899351010C134018914 @default.
• W1899351010 hasConceptScore W1899351010C164027704 @default.
• W1899351010 hasConceptScore W1899351010C203014093 @default.
• W1899351010 hasConceptScore W1899351010C2776151105 @default.
• W1899351010 hasConceptScore W1899351010C2776914184 @default.
• W1899351010 hasConceptScore W1899351010C2777074287 @default.
• W1899351010 hasConceptScore W1899351010C2777658100 @default.
• W1899351010 hasConceptScore W1899351010C2778690821 @default.
• W1899351010 hasConceptScore W1899351010C2779769559 @default.
• W1899351010 hasConceptScore W1899351010C2779980618 @default.
• W1899351010 hasConceptScore W1899351010C502942594 @default.
• W1899351010 hasConceptScore W1899351010C54355233 @default.
• W1899351010 hasConceptScore W1899351010C71924100 @default.
• W1899351010 hasConceptScore W1899351010C81885089 @default.
• W1899351010 hasConceptScore W1899351010C86803240 @default.
• W1899351010 hasConceptScore W1899351010C8891405 @default.
• W1899351010 hasIssue "2" @default.

• next